CORRELATIONS BETWEEN INTERLEUKIN LEVELS AND INDICES OF CELL-MEDIATED AND HUMORAL IMMUNITIES IN PATIENTS WITH MULTIPLE SCLEROSIS IN DIFFERENT COURSES OF THE DISEASE
DOI:
https://doi.org/10.11603/mcch.2410-681X.2019.v.i4.10844Keywords:
multiple sclerosis, correlation, cytokines, lymphocytes, immunoglobulins, circulating immune complexesAbstract
Introduction. Multiple sclerosis (MS) is considered the "most mysterious" nerve disease due to its volatility, instability and unpredictability, and research on the immune system is an integral part of the diagnosis of the disease. Therefore, a clearer idea of the immunological mechanisms in various forms of MS, correlation of their indicators will not only improve the diagnosis and deepen our knowledge of pathogenesis, but can also be the basis for improving pathogenetic treatment with the use of various immunotherapeutic agents.
The aim of the study – to find out the features of correlation of immunopathogenesis indices, cytokine, humoral and cell immunity in patients with multiple sclerosis with different types of the course.
Research Methods. The results of the studies were analyzed by the method of variational statistics using STATISTICA 8.0 (Statsoft, USA).
Results and Discussion. Levels of interleukins 1β, 2, 33, TNF- α, immunoglobulins А, G, M and the content of circulating immune complexes (CIC), as well as СD3+, СD4+, СD8+, СD19+, СD25+, СD56+ lymphocytes were studied in all individuals under investigation. A reliable increase in IgA concentration in blood serum of patients with MS indicates infection of the mucosa. It was especially marked in patients with primary progressive form of MS. Significant increase in IgG and IgM levels in blood serum of patients with MS indicates a chronic course of the process. It is especially evident in relapsing-remitting form of MS. Fluctuations in mean content of circulating immune complexes in blood serum of patients with MS indicate the severity degree of immunopathological process. A significant number of strong and moderate correlations between indices of immune status and the levels of interleukins IL-1β, IL-2, IL-33 and TNF-α has been revealed in the group of patients with secondary progressive type of MS. The level of IL-2 in all investigated groups of patients with PC constituted the highest number of correlations with immune status indices, which proves its important role in MS pathogenesis.
Conclusion. Investigation of cytokine correlations as well as other indices of humoral and cellular immunity in patients with MS is a relevant and promising area for studying the mechanisms of PC immunopathogenesis and its correction.
References
Compston, A., & Coles, A. (2008). Multiple sclerosis. Lancet, 372 (9648), 1502-1517. PMID 18970977. doi:10.1016/S0140-6736(08)61620-7. DOI: https://doi.org/10.1016/S0140-6736(08)61620-7
Poiman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol., 69 (2), 292-302.
Vorobyeva, A.A., Ivanova, M.V., Fominykh, V.V., Zakharova, M.N., Zygangyrova, G.A., & Gulyaeva, N.V. (2013). Biomarkery rasseyannogo skleroza (obzor i sobstvennyye dannyye) [Multiple sclerosis biomarkers (review and own data)]. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry, 113 (10), 23-31 [in Russiаn].
Voloshina, N.P., Levchenko, I.L., & Negreba, T.V. (2011). Gendernyye osobennosti immunnogo statusa pri progrediyentnykh tipakh techeniya rasseyannogo skleroza [Gender features of immune status in progressive types of multiple sclerosis]. Ukr. vestnik psikhonevrologii – Ukrainian Bulletin of Psychoneurology, 19 (4), 5-9 [in Russiаn].
Gulyayeva, S.Ye., Ivanushka, L.A., Ovchinnikov, A.V., Besednova, N.A., Korotkova, M.A., Sharkova, V.A. (2010). Disbalans tsitokinov kak odin iz prognosticheskikh kriteriyev rasseyannogo skleroza [An imbalance of cytokines as one of the prognostic criteria for multiple sclerosis]. Tikhookeanskiy meditsinskiy zhurnal – Pacific Medical Journal, 42 (4), 55-58 [in Russiаn].
Tsang, B.K., & Macdonell, R. (2011). Multiple sclerosis-diagnosis, management and prognosis. Aust. Fam. Physician, 40 (12), 948-955.
Boyko, A.N., Boyko, A.V., Gusev, Ye.I. (2014). Vybor optimalnogo preparata dlya patogeneticheskogo lecheniya rasseyannogo skleroza: sovremennoye sostoyaniye problemy (obzor literatury) [Choosing the best drug for the pathogenetic treatment of multiple sclerosis: the current state of the problem (literature review)]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry, 20, 114 (10), 77-91 [in Russiаn].
Makarov, S.V. (2014). Kliniko-immunologicheskaya kharakteristika bolnykh s remittiruyushchim i progressiruyushchim techeniyem rasseyannogo skleroza [Clinical and immunological characteristics of patients with remitting and progressing course of multiple sclerosis]. Fundamentalnyye issledovaniya – Basic Research, 4, 546-550 [in Russiаn].
Bisaga, A.N., Odinochka, M.M., & Boyko, A.N. (2011). Vozmozhnosti lecheniya obostreniy rasseyannogo skleroza bez primeneniya kortikosteroidov: rol metabolicheskoy i antioksidantnoy terapii [Possibilities of treating exacerbations of multiple sclerosis without corticosteroids: the role of metabolic and antioxidant therapy]. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry, 111 (2), 44-48 [in Russiаn].
Delov, G.A., Rozhdestvenskiy, A.S., & Marks, Y.A. (2013). Kliniko-elektrofiziologicheskaya i molekulyarno-geneticheskaya kharakteristika techeniya remittiruyushchego rasseyannogo skleroza [Clinical-electrophysiological and molecular-genetic characteristics of the course of remitting multiple sclerosis]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova – S.S. Korsakov Journal of Neurology and Psychiatry, 113 (10), 55-59 [in Russiаn].
McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D. (Eds.). (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol., 50 (1), 121-127. DOI: https://doi.org/10.1002/ana.1032
